Akari Therapeutics (AKTX) Cash from Financing Activities (2014 - 2026)

Akari Therapeutics has disclosed Cash from Financing Activities across 8 years of filings, most recently posting $53000.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $53000.0, down 97.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.1 million (down 4.45% YoY), and the FY2025 annual result was $13.2 million, up 19.87% from the prior year.
• Cash from Financing Activities came in at $53000.0 for Q1 2026 at Akari Therapeutics, down from $5.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $7.8 million in Q2 2024 to a low of -$443000.0 in Q3 2024.
• The 4-year median for Cash from Financing Activities is $2.1 million (2024), against an average of $2.6 million.
• Across the five-year window, Cash from Financing Activities jumped 2567.7% in 2024 and plunged 97.52% in 2026, its largest moves.
• Akari Therapeutics' Cash from Financing Activities stood at $3.5 million in 2023, then plunged by 38.75% to $2.2 million in 2024, then jumped by 167.41% to $5.8 million in 2025, then sank by 99.08% to $53000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $53000.0 (Q1 2026), $5.8 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.